Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/27330| Conference/Presentation Title: | Glomerulonephritis. | Authors: | Chadban S.J.;Atkins R.C. | Institution: | (Chadban, Atkins) Department of Nephrology, Monash Medical Centre, Clayton, Vic., Australia (Chadban) Renal Medicine and Transplantation, Royal Prince Alfred Hospital, University of Sydney, Camperdown, NSW, Australia (Chadban) Transplantation, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia | Presentation/Conference Date: | 17-Oct-2012 | Copyright year: | 2005 | Publisher: | Elsevier B.V. Elsevier Limited (32 Jamestown Road, London NW1 7BY, United Kingdom) |
Publication information: | Lancet. 365 (9473) (pp 1797-1806), 2005. Date of Publication: 21 May 2005. | Journal: | The Lancet | Abstract: | The term glomerulonephritis encompasses a range of immune-mediated disorders that cause inflammation within the glomerulus and other compartments of the kidney. Studies with animal models have shown the crucial interaction between bone-marrow-derived inflammatory cells and cells intrinsic to the kidney that is both fundamental and unique to the pathogenesis of glomerulonephritis. The mechanisms of interaction between these cells and the mediators of their coordinated response to inflammation are being elucidated. Despite these pathophysiological advances, treatments for glomerulonephritis remain non-specific, hazardous, and only partly successful. Glomerulonephritis therefore remains a common cause of end-stage kidney failure worldwide. Molecule-specific approaches offer hope for more effective and safer treatments in the future. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/S0140-6736%2805%2966583-X | PubMed URL: | 15910953 [http://www.ncbi.nlm.nih.gov/pubmed/?term=15910953] | ISSN: | 0140-6736 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/27330 | Type: | Conference Paper | Subjects: | *glomerulonephritis/dt [Drug Therapy] *glomerulonephritis/ep [Epidemiology] *glomerulonephritis/et [Etiology] *glomerulonephritis/su [Surgery] *glomerulonephritis/th [Therapy] glomerulosclerosis/dt [Drug Therapy] glomerulus filtration rate Goodpasture syndrome/th [Therapy] hematuria Heymann nephritis human hyperlipidemia/dt [Drug Therapy] immune system immunoglobulin A nephropathy/dt [Drug Therapy] immunosuppressive treatment infection/si [Side Effect] infection risk infection sensitivity inflammation kidney biopsy kidney cell kidney disease kidney failure/dt [Drug Therapy] cyclophosphamide/po [Oral Drug Administration] kidney transplantation leukocyte lung hemorrhage lupus erythematosus nephritis/dt [Drug Therapy] membranoproliferative glomerulonephritis/dt [Drug Therapy] membranous glomerulonephritis/dt [Drug Therapy] minimal change glomerulonephritis/dt [Drug Therapy] nephrotic syndrome nonhuman pathogenesis plasmapheresis priority journal protein restriction proteinuria/si [Side Effect] rapidly progressive glomerulonephritis/dt [Drug Therapy] rapidly progressive glomerulonephritis/th [Therapy] risk assessment sex ratio side effect/si [Side Effect] T cell depletion treatment outcome vasculitis/dt [Drug Therapy] angiotensin receptor antagonist/dt [Drug Therapy] antibody/dt [Drug Therapy] dipeptidyl carboxypeptidase inhibitor/dt [Drug Therapy] hirudin/dt [Drug Therapy] hirudin/pd [Pharmacology] imatinib/dt [Drug Therapy] imatinib/pd [Pharmacology] immunosuppressive agent/ae [Adverse Drug Reaction] immunosuppressive agent/dt [Drug Therapy] immunosuppressive agent/iv [Intravenous Drug Administration] antibody/pd [Pharmacology] antilipemic agent/dt [Drug Therapy] azathioprine/ae [Adverse Drug Reaction] azathioprine/dt [Drug Therapy] azathioprine/po [Oral Drug Administration] azathioprine/pd [Pharmacology] CD20 antibody/dt [Drug Therapy] chlorambucil/ae [Adverse Drug Reaction] chlorambucil/dt [Drug Therapy] chlorambucil/po [Oral Drug Administration] chlorambucil/pd [Pharmacology] corticosteroid/ae [Adverse Drug Reaction] corticosteroid/dt [Drug Therapy] corticosteroid/pd [Pharmacology] cyclophosphamide/ae [Adverse Drug Reaction] cyclophosphamide/dt [Drug Therapy] cyclophosphamide/iv [Intravenous Drug Administration] immunosuppressive agent/po [Oral Drug Administration] immunosuppressive agent/pd [Pharmacology] intercellular adhesion molecule 1 antibody/dt [Drug Therapy] intercellular adhesion molecule 1 antibody/pd [Pharmacology] interleukin 1 receptor blocking agent/dt [Drug Therapy] interleukin 1 receptor blocking agent/pd [Pharmacology] interleukin 10/dt [Drug Therapy] interleukin 10/pd [Pharmacology] mycophenolic acid 2 morpholinoethyl ester/ae [Adverse Drug Reaction] mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy] mycophenolic acid 2 morpholinoethyl ester/pd [Pharmacology] n(g) nitroarginine methyl ester/dt [Drug Therapy] n(g) nitroarginine methyl ester/pd [Pharmacology] nitric oxide synthase inhibitor/dt [Drug Therapy] nitric oxide synthase inhibitor/pd [Pharmacology] oligonucleotide/dt [Drug Therapy] oligonucleotide/pd [Pharmacology] prednisone/do [Drug Dose] prednisone/dt [Drug Therapy] prednisone/po [Oral Drug Administration] rapamycin/ae [Adverse Drug Reaction] rapamycin/dt [Drug Therapy] rapamycin/pd [Pharmacology] steroid/dt [Drug Therapy] thrombin inhibitor/dt [Drug Therapy] thrombin inhibitor/pd [Pharmacology] unclassified drug colony stimulating factor receptor antibody/dt [Drug Therapy] colony stimulating factor receptor antibody/pd [Pharmacology] monocyte chemotactic protein 1 antibody/dt [Drug Therapy] monocyte chemotactic protein 1 antibody/pd [Pharmacology] kidney failure/pc [Prevention] cyclophosphamide/pd [Pharmacology] cyclosporin/dt [Drug Therapy] acute kidney failure/si [Side Effect] Alport syndrome antibody dependent cellular cytotoxicity blood clotting cancer susceptibility cellular immunity chronic glomerulonephritis complement system conference paper diagnostic procedure disease association drug efficacy drug induced cancer/si [Side Effect] drug safety *glomerulonephritis / *drug therapy / *epidemiology / *etiology / *surgery / *therapy glomerulosclerosis / drug therapy glomerulus filtration rate Goodpasture syndrome / therapy hematuria Heymann nephritis human hyperlipidemia / drug therapy immune system immunoglobulin A nephropathy / drug therapy immunosuppressive treatment infection / side effect infection risk infection sensitivity inflammation kidney biopsy kidney cell kidney disease kidney failure / drug therapy / prevention kidney transplantation leukocyte lung hemorrhage lupus erythematosus nephritis / drug therapy membranoproliferative glomerulonephritis / drug therapy membranous glomerulonephritis / drug therapy minimal change glomerulonephritis / drug therapy nephrotic syndrome nonhuman pathogenesis plasmapheresis priority journal protein restriction proteinuria / side effect cellular immunity risk assessment sex ratio side effect / side effect T cell depletion treatment outcome vasculitis / drug therapy cancer susceptibility blood clotting antibody dependent cellular cytotoxicity Alport syndrome acute kidney failure / side effect rapidly progressive glomerulonephritis / drug therapy / therapy chronic glomerulonephritis complement system conference paper diagnostic procedure disease association drug efficacy drug induced cancer / side effect drug safety |
| Appears in Collections: | Conferences |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.